PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS

Protocol: 
AAAR3715
Phase: 
II

PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS

The study intervention consists of the early integration of palliative care
services into standard oncology care in an outpatient setting for patients
with advanced lung and non-colorectal gastrointestinal malignancies who are
not being treated with curative intent. The palliative care services
provided
to patients randomized to the intervention will be provided by board
certified
physicians and/or advanced practice nurses and will focus on the following
areas: (1) developing and maintaining the therapeutic relationship with the
patients and family caregivers; (2) assessing and treating patient symptoms;
(3) providing support and reinforcement of coping with advanced cancer in
patients and family caregivers; (4) assessing and enhancing prognostic
awareness and illness understanding in patients and family caregivers; (5)
assisting with treatment decision-making; and (6) end-of-life care planning.

Are you Eligible? (Inclusion Criteria)

1. Age ≥ 18 years
2. No prior chemotherapy or radiation for pancreatic cancer and no
definitive
resection of pancreatic cancer.
3. ECOG Performance Status 0 or 1
4. Not pregnant and not nursing - For women of childbearing potential only,
a
negative pregnancy test done less than 7 days prior to registration is
required.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States